Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 3 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | February 2012 |
| End Date: | December 2016 |
This is a second Pilot Study to determine the efficacy of Gleevec® in neurofibromatosis
(NF1) patients with plexiform neurofibromas using new response assessment modalities with
the secondary goals of assessing Gleevec toxicity, and characterizing markers of response.
The rationale for this study arises from the response of human and murine NF1 cells to
Gleevec® in vitro, the response of a NF1 patient treated with Gleevec® for airway
compression by a plexiform neurofibroma with a dramatic response not previously seen in NF1
therapy, and the experience in 37 NF1 patients treated with Gleevec® in the initial pilot
study. Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients
with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients
with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as
tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will
increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of
220 mg/m2 bid. Treatment will continue for 6 months with an option to continue for 24 months
if the patient is deriving a clinical benefit.
(NF1) patients with plexiform neurofibromas using new response assessment modalities with
the secondary goals of assessing Gleevec toxicity, and characterizing markers of response.
The rationale for this study arises from the response of human and murine NF1 cells to
Gleevec® in vitro, the response of a NF1 patient treated with Gleevec® for airway
compression by a plexiform neurofibroma with a dramatic response not previously seen in NF1
therapy, and the experience in 37 NF1 patients treated with Gleevec® in the initial pilot
study. Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients
with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients
with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as
tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will
increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of
220 mg/m2 bid. Treatment will continue for 6 months with an option to continue for 24 months
if the patient is deriving a clinical benefit.
Inclusion criteria
1. Patients > 3 years of age.
2. Diagnosis of neurofibromatosis type 1 (NF1).
3. Presence of clinically significant plexiform neurofibromas (biopsy proven if possible
with tissue blocks available); defined as tumors that are potentially life
threatening or are impinging on vital structures or significantly impair the quality
of life from pain or other symptoms.
4. Patients must have measurable disease by magnetic resonance imaging (MRI).
5. Patients must have a Karnofsky of > 70% or Lansky of > 50% and a life expectancy of >
2 months.
6. Adequate end organ function, defined as the following:
total bilirubin < 1.5 x ULN, SGOT and SGPT < 2.5 x UNL, creatinine < 1.5 x ULN, ANC >
1.5 x 109/L, platelets > 100 x 109/L.
7. Patients must be able to swallow whole pills.
8. Female patients of childbearing potential must have negative pregnancy test within 7
days before initiation of study drug dosing. Postmenopausal women must be amenorrheic
for at least 12 months to be considered of non-childbearing potential. Male and
female patients of reproductive potential must agree to employ an effective barrier
method of birth control throughout the study and for up to 3 months following
discontinuation of study drug.
9. Written, voluntary informed consent.
Exclusion criteria
1. Patient has received any other investigational agents within 28 days of first day of
study drug dosing, unless the disease is rapidly progressing.
2. Patient is < 5 years free of another primary malignancy except: if the other primary
malignancy is not currently clinically significant nor requiring active intervention,
or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in
situ. Existence of any other malignant disease is not allowed.
3. Patient with Grade III/IV cardiac problems as defined by the New York Heart
Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6
months of study)
4. Female patients who are pregnant or breast-feeding.
5. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled
diabetes, chronic renal disease, or active uncontrolled infection).
6. Patient has a known brain metastasis. Non-specific CNS changes on MRI/CT
characteristic of NF1 are allowed, but not known CNS malignancies.
7. Patient has known chronic liver disease (i.e., chronic active hepatitis, and
cirrhosis).
8. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
9. Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C)
prior to study entry, unless the disease is rapidly progressing.
10. Patient previously received radiotherapy to greater than or equal to 25 % of the bone
marrow
11. Patient had a major surgery within 2 weeks prior to study entry.
12. Patient with any significant history of non-compliance to medical regimens or with
inability to grant reliable informed consent.
13. Patients who have or anticipate receiving permanent (or semi-permanent) metallic
structures attached to their body. (e.g., braces on teeth, body piercings), which
their physicians believe will interfere with the MRI.
We found this trial at
1
site
Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...
Click here to add this to my saved trials
